Relative bioavailability of scopolamine dosage forms and interaction with dextroamphetamine
Jason L Boyd1, Brian Du, Zalman Vaksman
1Universities Space Research Association, Houston, TX, USA.
Abstract:
The NASA Reduced Gravity Office (RGO) uses scopolamine (SCOP) alone and in combination with dextoamphetamine (DEX) to treat motion sickness symptoms during DC-9 parabolic flights. The medications are sometimes dispensed as custom dosage forms in gelatin capsules for convenience. Reports of treatment failure during flights by the flight surgeons suggest that these formulations may be less efficacious for the treatment of motion sickness due to unreliable and inadequate bioavailability. We estimated bioavailability of four different oral formulations used by the NASA RGO physicians for the treatment of motion sickness.
Related Concept Videos
Cholinergic Antagonists: Pharmacokinetics
Modified-Release Drug Delivery Systems: Bioavailability
Indirect-Acting Cholinergic Agonists: Pharmacokinetics
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they are...
Bioavailability: Influencing Factors
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Bioavailability: Overview
